TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company that focuses on the development of novel T-cell therapies for the treatment of cancer. The company’s proprietary TRuC™ (TCR Fusion Construct) platform enables the production of T cells with enhanced persistence and effector function for solid tumor indications.
TCR2’s pipeline includes both autologous and allogeneic TRuC-T cells, which are designed to recognize and kill cancer cells with high specificity. The lead candidate, gavo-cel, is an autologous therapy targeting the HLA-A2-restricted MAGE-A4 antigen in patients with solid tumors. The company has also developed a proprietary manufacturing process that enables the scalable production of TRuC-T cells, which could potentially reduce the time and cost of manufacturing compared to other cell therapies.
In addition to gavo-cel, TCR2 has several other TRuC-T cell candidates in preclinical development targeting other cancer antigens, as well as a collaboration with Novartis to develop TRuC-T cells for solid tumor indications.
Founded in 2015 and headquartered in Cambridge, Massachusetts, TCR2 went public in 2019 and is traded on the NASDAQ stock exchange under the ticker symbol TCRR.
|
